今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

王宝强黄渤角逐影帝！第四届新时代电影节提名揭晓，多位实力派演员同台竞技

澳门 - 由1978卓越大奖(1978Excellence Awards)举办的第四届新时代国际电影节于2023年12月10日在澳门永利皇宫举行盛大颁奖典礼。本届电影节以“弘扬新时代精神，助力中国电影发展”为主题，旨在表彰在新时代取得突出成绩的电影作品和电影人。

王宝强斩获影帝实至名归 《八角笼中》成最大赢家

经过多轮评选，最终，《毒舌律师》《八角笼中》《流浪地球2》《满江红》《宇宙探索编辑部》五部电影获得最佳影片提名。王宝强、黄渤、大鹏、胡歌和杨皓宇五位实力派演员则角逐最佳男主角奖项。

最终，王宝强凭借在电影《八角笼中》中饰演的[角色名称]一角，击败黄渤等强劲对手，斩获最佳男主角奖。这是王宝强演艺生涯中首次获得影帝殊荣，也是对他在电影表演方面多年耕耘的肯定。

电影《八角笼中》也获得了最佳影片、最具潜力导演、最具潜力女演员奖三项大奖，成为本届电影节的最大赢家。

其他提名奖项 实力派演员同台竞技

最佳女主角方面，惠英红、海清、佟丽娅、闫妮和艾丽娅五位实力派女演员获得提名。最终，惠英红凭借在电影《[电影名称]》中的出色表现，获得最佳女主角奖。

其他提名奖项获奖名单如下：

• 最佳导演：[导演姓名] - 《[电影名称]》
• 最佳男配角：[演员姓名] - 《[电影名称]》
• 最佳女配角：[演员姓名] - 《[电影名称]》
• 最佳编剧：[编剧姓名] - 《[电影名称]》
• 最佳音乐：[音乐人姓名] - 《[电影名称]》
• 最佳摄影：[摄影师姓名] - 《[电影名称]》
• 最佳美术：[美术师姓名] - 《[电影名称]》
• 最佳剪辑：[剪辑师姓名] - 《[电影名称]》
• 最佳服装设计：[服装设计师姓名] - 《[电影名称]》
• 最佳动作设计：[动作指导姓名] - 《[电影名称]》
• 最佳音效：[音效师姓名] - 《[电影名称]》
• 最佳视觉效果：[视觉效果师姓名] - 《[电影名称]》

新时代电影节表彰优秀作品 弘扬新时代精神

第四届新时代国际电影节的成功举办，为广大电影人提供了展示才华、交流切磋的平台，也为观众带来了众多优秀电影作品。相信在新时代电影节的引领下，中国电影将不断发展壮大，创作出更多精品力作，为观众带来更多精神文化享受。

### 第四届新时代国际电影节获奖名单

• 最佳影片：《八角笼中》
• 最佳导演：[导演姓名] - 《[电影名称]》
• 最佳男主角：王宝强 - 《八角笼中》
• 最佳女主角：惠英红 - 《[电影名称]》
• 其他奖项略...